Phase I/II study to evaluate the efficacy and safety of PAZOPANIB in combination with TEMOZOLOMIDE as maintenance therapy in Glioblastoma patients undergoing surgery and subsequently treated with induction radiotherapy-TEMOZOLOMIDE

2024-510960-22-00 Phase I and Phase II (Integrated) - Other Ongoing, recruitment ended

Start 25 Jun 2015 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 5 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruitment ended
Participants planned 56
Countries 1
Sites 5

gliobastoma

Key facts

Sponsor
Centre Antoine Lacassagne
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
25 Jun 2015 → ongoing
Decision date (initial)
2024-04-22
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-510960-22-00
EudraCT number
2014-001578-32
ClinicalTrials.gov
NCT02331498

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

gliobastoma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Antoine Lacassagne

Sponsor organisation
Centre Antoine Lacassagne
Address
33 Avenue De Valombrose
City
Nice Cedex 2
Postcode
06189
Country
France

Scientific contact point

Organisation
Centre Antoine Lacassagne
Contact name
Dr Esma SAADA-BOUZID

Public contact point

Organisation
Centre Antoine Lacassagne
Contact name
Dr Esma SAADA-BOUZID

Locations

1 EU/EEA country · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 56 5
Rest of world 0

Investigational sites

France

5 sites · Ongoing, recruitment ended
Assistance Publique Hopitaux De Marseille
neuro-oncology, 264 Rue Saint Pierre, 13005, Marseille
Centre Hospitalier Universitaire De Nice
Neurology, 30 Voie Romaine, 06000, Nice
Institut De Cancerologie De L Ouest
Oncology, Bd Du Professeur Jacques Monod, 44800, St Herblain
Institut De Cancerologie De L Ouest
Medical oncology, 15 Rue Andre Boquel, 49100, Angers
Centre Antoine Lacassagne
Oncology, 33 Avenue De Valombrose, 06189, Nice Cedex 2

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2015-06-25 2015-06-25 2026-04-29

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-31 France Acceptable
2024-04-15
2024-04-22
2 SUBSTANTIAL MODIFICATION SM-1 2024-07-11 France Acceptable
2024-09-23
2024-09-23
3 SUBSTANTIAL MODIFICATION SM-3 2025-09-09 France Acceptable
2025-10-07
2025-10-20